BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 15, 2025
See today's BioWorld Asia
Home
» CAT, Abbott Settle Humira Dispute: Abbott Pays $255M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
CAT, Abbott Settle Humira Dispute: Abbott Pays $255M
Nov. 2, 2005
By
Karen Carey
No Comments
Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. (BioWorld International)
BioWorld Asia